We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Monthly Production Capacity: large capacity
Contract Manufacturing: Workable
Packaging Information: According to customs' requirements
Delivery Lead Time: USP, BP, EP etc
Sample Provided: no
Payment Terms: depends, normally about 2 months
Product : Cefoperazone Sodium and Sulbactam Sodium for Injection 2:1; 1:1
Specification : 0.75g; 1.5g; 2.0g; 2.25g; 3.0g
Standard : BP, USP
Description:
Cefoperazone is a semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections.
Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics.
Indication
For the treatment of bacterial infections caused by susceptible microorganisms.
Pharmacodynamics
Cefoperazone is a third generation cephalosporin antibiotic. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis
Mechanism of action
Like all beta-lactam antibiotics, cefoperazone binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
